FY2024 EPS Estimates for Amedisys Reduced by William Blair

Amedisys, Inc. (NASDAQ:AMED) – Analysts at William Blair cut their FY2024 earnings per share (EPS) estimates for shares of Amedisys in a research note issued on Thursday, November 7th. William Blair analyst M. Larew now expects that the health services provider will post earnings per share of $4.40 for the year, down from their previous forecast of $4.72. The consensus estimate for Amedisys’ current full-year earnings is $4.62 per share. William Blair also issued estimates for Amedisys’ Q4 2024 earnings at $1.05 EPS and Q3 2025 earnings at $1.10 EPS.

A number of other brokerages have also issued reports on AMED. Cantor Fitzgerald reissued a “neutral” rating and set a $101.00 price target on shares of Amedisys in a research note on Thursday, July 25th. Deutsche Bank Aktiengesellschaft lowered Amedisys from a “buy” rating to a “hold” rating and set a $101.00 price target for the company. in a research note on Monday, July 29th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $100.67.

Amedisys Price Performance

NASDAQ:AMED opened at $91.00 on Monday. The firm has a market capitalization of $2.98 billion, a price-to-earnings ratio of 36.11, a PEG ratio of 1.90 and a beta of 0.78. Amedisys has a 1 year low of $89.55 and a 1 year high of $98.95. The business has a 50 day simple moving average of $96.46 and a 200-day simple moving average of $95.89. The company has a debt-to-equity ratio of 0.34, a current ratio of 1.19 and a quick ratio of 1.16.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings data on Wednesday, November 6th. The health services provider reported $1.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.19 by ($0.19). The company had revenue of $587.67 million during the quarter, compared to the consensus estimate of $586.75 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. Amedisys’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.98 earnings per share.

Institutional Investors Weigh In On Amedisys

A number of institutional investors and hedge funds have recently modified their holdings of AMED. KBC Group NV purchased a new position in Amedisys during the 3rd quarter worth $63,000. Innealta Capital LLC purchased a new position in Amedisys during the 2nd quarter worth $64,000. Covestor Ltd increased its holdings in Amedisys by 134.2% during the 1st quarter. Covestor Ltd now owns 780 shares of the health services provider’s stock worth $72,000 after purchasing an additional 447 shares during the period. Signaturefd LLC increased its holdings in Amedisys by 88.2% during the 2nd quarter. Signaturefd LLC now owns 1,131 shares of the health services provider’s stock worth $104,000 after purchasing an additional 530 shares during the period. Finally, CWM LLC increased its holdings in Amedisys by 14.5% during the 3rd quarter. CWM LLC now owns 2,190 shares of the health services provider’s stock worth $211,000 after purchasing an additional 277 shares during the period. 94.36% of the stock is owned by institutional investors.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.